Compass Therapeutics Reports Executive Changes & Compensation on Jan 8

TL;DR

**Compass Therapeutics just filed an 8-K about executive changes and compensation, watch for details!**

AI Summary

Compass Therapeutics, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024, related to the departure or election of directors or officers and their compensatory arrangements, as well as other events. This filing indicates potential changes in leadership or executive compensation, which could impact the company's strategic direction and financial health. Investors should pay attention to subsequent details about these changes, as they can influence future performance and stock valuation.

Why It Matters

Changes in executive leadership and compensation can signal shifts in company strategy or financial stability, directly affecting investor confidence and stock performance.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty, but the specific details of this filing are not yet public, making the exact impact unknown.

Analyst Insight

A smart investor would monitor Compass Therapeutics, Inc. for subsequent filings or press releases that provide specific details about the executive changes and compensatory arrangements mentioned in this 8-K, as these specifics will determine the actual impact on the company.

Key Players & Entities

• Compass Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of the earliest event reported
• January 9, 2024 (date) — date the 8-K was filed
• 001-39696 (other) — Commission File Number
• CMPX (other) — trading symbol for Common Stock
• NASDAQ (other) — exchange where Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CMPX NASDAQ Cap
• $600,000 — d agreed to increase her base salary to $600,000 from $500,000 and her target annual bon
• $500,000 — crease her base salary to $600,000 from $500,000 and her target annual bonus to 55% from
• $1.93 — on the January 9, 2024 date of grant of $1.93 per share and Restricted Stock Units ("
• $152 million — arketable securities were approximately $152 million as of December 31, 2023. This amount is

Filing Documents

• f8k_010924.htm (8-K) — 27KB
• 0001171843-24-000164.txt ( ) — 200KB
• cmpx-20240108.xsd (EX-101.SCH) — 3KB
• cmpx-20240108_lab.xml (EX-101.LAB) — 33KB
• cmpx-20240108_pre.xml (EX-101.PRE) — 22KB
• f8k_010924_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In accordance with the previously announced succession plan, on January 8, 2024, the Board of Directors (the "Board") of Compass Therapeutics, Inc. (the "Company") appointed Vered Bisker-Leib, PhD as Chief Executive Officer of the Company and a member the Board, each effective January 9, 2024. Dr. Bisker-Leib will serve as a Class III director until the date of the annual meeting of stockholders to be held in 2026, or until her earlier death, resignation or removal. Dr. Bisker-Leib has been serving as President and Chief Operating Officer of the Company since August 2020, and will no longer serve in such capacities upon effectiveness of her appointment as Chief Executive Officer. In connection with Dr. Bisker-Leib's appointment as Chief Executive Officer of the Company, Dr. Bisker-Leib entered into an Employment Agreement with the Company, dated January 8, 2024 (the "Bisker-Leib Employment Agreement"). Pursuant to the Bisker-Leib Employment Agreement, the Board agreed to increase her base salary to $600,000 from $500,000 and her target annual bonus to 55% from 45% of her base salary. Dr. Bisker-Leib also received an award of stock options for 1,753,125 shares of common stock with an exercise price equal to the closing price on the Nasdaq Global Market on the January 9, 2024 date of grant of $1.93 per share and Restricted Stock Units ("RSUs") with respect to 1,753,125 shares of common stock. The options and RSUs granted to Dr. Bisker-Leib vest as follows: (i) with respect to the options, monthly over 48 months beginning on the one month anniversary of the date of grant, and (ii) with respect to the RSUs, 25% will vest annually over four years on the anniversary of the date of grant, in each case subject to Dr. Bisker-Leib's continued employment. Under the Bisker-Leib Employment Agreement, if Dr. Bisker-Leib

01

Item 8.01 Other Information As previously disclosed, the Company estimates that its cash, cash equivalents and marketable securities were approximately $152 million as of December 31, 2023. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company's financial statements as of and for the year ended December 31, 2023.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. COMPASS THERAPEUTICS, INC. Date: January 9, 2024 By: /s/ Neil Lerner Neil Lerner Vice President Finance

View Full Filing

View this 8-K filing on SEC EDGAR